Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166


Metabolic Footprints and Molecular Subtypes in Breast Cancer.

Cappelletti V, Iorio E, Miodini P, Silvestri M, Dugo M, Daidone MG.

Dis Markers. 2017;2017:7687851. doi: 10.1155/2017/7687851. Epub 2017 Dec 24. Review.


Metformin and cancer: An existing drug for cancer prevention and therapy.

Zi F, Zi H, Li Y, He J, Shi Q, Cai Z.

Oncol Lett. 2018 Jan;15(1):683-690. doi: 10.3892/ol.2017.7412. Epub 2017 Nov 14.


Cancer risk in patients with diabetic nephropathy: A retrospective cohort study in Hong Kong.

Cheung CY, Ma MKM, Chak WL, Tang SCW.

Medicine (Baltimore). 2017 Sep;96(38):e8077. doi: 10.1097/MD.0000000000008077.


Metformin increases chemo-sensitivity via gene downregulation encoding DNA replication proteins in 5-Fu resistant colorectal cancer cells.

Kim SH, Kim SC, Ku JL.

Oncotarget. 2017 May 11;8(34):56546-56557. doi: 10.18632/oncotarget.17798. eCollection 2017 Aug 22.


Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis.

Dong YW, Shi YQ, He LW, Cui XY, Su PZ.

Oncotarget. 2017 May 26;8(33):55478-55488. doi: 10.18632/oncotarget.18233. eCollection 2017 Aug 15.


Critical role for arginase 2 in obesity-associated pancreatic cancer.

Zaytouni T, Tsai PY, Hitchcock DS, DuBois CD, Freinkman E, Lin L, Morales-Oyarvide V, Lenehan PJ, Wolpin BM, Mino-Kenudson M, Torres EM, Stylopoulos N, Clish CB, Kalaany NY.

Nat Commun. 2017 Aug 14;8(1):242. doi: 10.1038/s41467-017-00331-y.


Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer.

Chen K, Qian W, Jiang Z, Cheng L, Li J, Sun L, Zhou C, Gao L, Lei M, Yan B, Cao J, Duan W, Ma Q.

Mol Cancer. 2017 Jul 24;16(1):131. doi: 10.1186/s12943-017-0701-0.


The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis.

Li X, Li T, Liu Z, Gou S, Wang C.

Sci Rep. 2017 Jul 19;7(1):5825. doi: 10.1038/s41598-017-06207-x.


Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.

Tajima H, Makino I, Ohbatake Y, Nakanuma S, Hayashi H, Nakagawara H, Miyashita T, Takamura H, Ohta T.

Oncol Lett. 2017 Jun;13(6):3975-3981. doi: 10.3892/ol.2017.6008. Epub 2017 Apr 7.


Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis.

Zhou PT, Li B, Liu FR, Zhang MC, Wang Q, Li YY, Xu C, Liu YH, Yao Y, Li D.

Oncotarget. 2017 Apr 11;8(15):25242-25250. doi: 10.18632/oncotarget.15692. Review.


High Glucose Accelerates Cell Proliferation and Increases the Secretion and mRNA Expression of Osteopontin in Human Pancreatic Duct Epithelial Cells.

Ito M, Makino N, Matsuda A, Ikeda Y, Kakizaki Y, Saito Y, Ueno Y, Kawata S.

Int J Mol Sci. 2017 Apr 12;18(4). pii: E807. doi: 10.3390/ijms18040807.


Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer.

Hart PA, Bellin MD, Andersen DK, Bradley D, Cruz-Monserrate Z, Forsmark CE, Goodarzi MO, Habtezion A, Korc M, Kudva YC, Pandol SJ, Yadav D, Chari ST; Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer(CPDPC).

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):226-237. doi: 10.1016/S2468-1253(16)30106-6. Epub 2016 Oct 12. Review.


New insight for metformin against bladder cancer.

El-Arabey AA.

Genes Environ. 2017 Apr 1;39:13. doi: 10.1186/s41021-017-0074-z. eCollection 2017. Review.


Metformin Inhibits Migration and Invasion of Cholangiocarcinoma Cells

Trinh SX, Nguyen HT, Saimuang K, Prachayasittikul V, Chan On W.

Asian Pac J Cancer Prev. 2017 Feb 1;18(2):473-477.


Complications of Chronic Pancreatitis.

Ramsey ML, Conwell DL, Hart PA.

Dig Dis Sci. 2017 Jul;62(7):1745-1750. doi: 10.1007/s10620-017-4518-x. Epub 2017 Mar 9. Review.


PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.

Vella V, Nicolosi ML, Giuliano S, Bellomo M, Belfiore A, Malaguarnera R.

Front Endocrinol (Lausanne). 2017 Feb 22;8:31. doi: 10.3389/fendo.2017.00031. eCollection 2017. Review.


Prognostic role of metformin intake in diabetic patients with colorectal cancer: An updated qualitative evidence of cohort studies.

Du L, Wang M, Kang Y, Li B, Guo M, Cheng Z, Bi C.

Oncotarget. 2017 Apr 18;8(16):26448-26459. doi: 10.18632/oncotarget.14688.


Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation.

Farmer RE, Ford D, Forbes HJ, Chaturvedi N, Kaplan R, Smeeth L, Bhaskaran K.

Int J Epidemiol. 2017 Apr 1;46(2):728-744. doi: 10.1093/ije/dyw275. Erratum in: Int J Epidemiol. 2017 Apr 1;46(2):745.


Chronic Pancreatitis in the 21st Century - Research Challenges and Opportunities: Summary of a National Institute of Diabetes and Digestive and Kidney Diseases Workshop.

Uc A, Andersen DK, Bellin MD, Bruce JI, Drewes AM, Engelhardt JF, Forsmark CE, Lerch MM, Lowe ME, Neuschwander-Tetri BA, OʼKeefe SJ, Palermo TM, Pasricha P, Saluja AK, Singh VK, Szigethy EM, Whitcomb DC, Yadav D, Conwell DL.

Pancreas. 2016 Nov;45(10):1365-1375.


Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: A window of opportunity study.

Soliman PT, Zhang Q, Broaddus RR, Westin SN, Iglesias D, Munsell MF, Schmandt R, Yates M, Ramondetta L, Lu KH.

Gynecol Oncol. 2016 Dec;143(3):466-471. doi: 10.1016/j.ygyno.2016.10.011. Epub 2016 Oct 13.

Supplemental Content

Support Center